145. Nat Rev Cancer. 2018 May 10. doi: 10.1038/s41568-018-0022-7. [Epub ahead ofprint]Author Correction: Inflammatory breast cancer biology: the tumourmicroenvironment is key.Lim B(1)(2), Woodward WA(3)(4), Wang X(5)(3), Reuben JM(3)(6), Ueno NT(7)(8).Author information: (1)Department of Breast Medical Oncology, The University of Texas MD AndersonCancer Center, Houston, TX, USA. blim@mdanderson.org.(2)Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, TheUniversity of Texas MD Anderson Cancer Center, Houston, TX, USA.blim@mdanderson.org.(3)Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, TheUniversity of Texas MD Anderson Cancer Center, Houston, TX, USA.(4)Department of Radiation Oncology, The University of Texas MD Anderson CancerCenter, Houston, TX, USA.(5)Department of Breast Medical Oncology, The University of Texas MD AndersonCancer Center, Houston, TX, USA.(6)Department of Hematopathology, The University of Texas MD Anderson CancerCenter, Houston, TX, USA.(7)Department of Breast Medical Oncology, The University of Texas MD AndersonCancer Center, Houston, TX, USA. nueno@mdanderson.org.(8)Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, TheUniversity of Texas MD Anderson Cancer Center, Houston, TX, USA.nueno@mdanderson.org.Erratum for    Nat Rev Cancer. 2018 Apr 27;:.The originally published article contained an error in Table 1, in which twoneoadjuvant clinical trials (NCT02876107 and NCT03101748) were not included. Thisomission has been corrected in the online and print versions of the manuscriptthrough the addition of these two trials and their relevant details (agents,cohort details, targeted biology, main targeted pathway or characteristic andphase) to Table 1.DOI: 10.1038/s41568-018-0022-7 PMID: 29748602 